Ropes & Gray represented AvenCell Therapeutics in the transaction, and Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction. AvenCell Therapeutics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vertos Medical Inc. on the transaction. Stryker (NYSE: SYK), a global leader in medical technologies, announced a definitive agreement to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised JP Morgan Life Sciences Private Capital on the transaction. Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Magenta Medical (Magenta) announced that it has raised $105 million in financing. The financing was...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction. Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced an...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, announced the close of a $103 million Series A...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised investor Novo Holdings on the transaction. Obsidian Therapeutics, Inc. (Obsidian), a clinical-stage biotechnology company, announced it closed an oversubscribed $160.5...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Foresight Diagnostics on the transaction. Allogene Therapeutics Inc. (Nasdaq: ALLO) and Foresight Diagnostics, announced a strategic partnership to develop a minimal residual...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is advising K18 on the transaction. Unilever announced it signed an agreement to acquire premium biotech haircare brand K18. Founded in 2020...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. MapLight Therapeutics announced a $225 million Series C financing co-led by Novo Holdings, 5AM Ventures, Cowen...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented SpyGlass in the transaction. SpyGlass Pharma announced the closing of $90 million in Series C financing. The financing, which was led...
You must be a Standard 1 Year member to access this content.
